What Happened?
Stony Brook, NY-based Black Diamond Therapeutics Appointed Michael Orfanos as Associate Director of Finance
About the Company
Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Using its mutation, allostery, and pharmacology (MAP) computational and discovery platform, Black Diamond is uncovering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant`s Ridgeline Discovery Engine in Basel, Switzerland.
About the Person
Michael Orfanos is Associate Director of Finance at Black Diamond Therapeutics. Previously, Michael held various senior HR leadership roles in the industry.
Info Source
News
Short Profile